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Flavin-containing monooxygenases (FMOs) metabolize 
numerous foreign chemicals, including drugs, pesticides 
and dietary components and, thus, mediate interactions 
between humans and their chemical environment. We 
describe the mechanism of action of FMOs and insights 
gained from the structure of yeast FMO. We then 
concentrate on the three FMOs (FMOs 1, 2 and 3) that are 
most important for metabolism of foreign chemicals in 
humans, focusing on the role of the FMOs and their genetic 
variants in disease and drug response. Loss-of-function 
mutations of FMO3 cause the disorder trimethylaminuria. 
More common variants that decrease enzyme activity are 
associated with increased drug efficacy. Most humans are 
homozygous for a nonsense mutation that inactivates 
FMO2. But a substantial proportion of sub-Saharan Africans 
express functional FMO2 and, thus, are predicted to 
respond differently to drugs and other foreign chemicals. 
Introduction 
Humans daily ingest a vast array of potentially harmful 
foreign chemicals. Fortunately, we possess enzymes that 
enable us to metabolize these chemicals into forms that 
are generally less toxic and more readily excreted. One 
such family of enzymes, the flavin-containing 
monooxygenases (FMOs, EC 1.14.13.8), catalyzes the 
oxygenation of a wide range of foreign chemicals, including 
therapeutic drugs, pesticides and dietary-derived 
compounds [1–3]. Thus, FMOs play an important 
protective role by mediating interactions between humans 
and their chemical environment.  
FMOs have been long overlooked, in comparison with 
the cytochromes P450 (CYPs), a larger and more 
extensively studied family of detoxification enzymes. 
However, characterization of members of the FMO family 
in humans and of the metabolic consequences of rare 
mutations and common polymorphic variants of FMOs has 
led to a growing appreciation of the pharmacological and 
toxicological significance of these enzymes [3,4]. In 
contrast to CYPs FMOs are generally not induced or 
inhibited by foreign chemicals, suggesting that therapeutic 
agents that are metabolized predominantly by FMOs 
would be less prone to drug–drug interactions [2]. 
Observed interindividual differences in the amount or 
activity of FMOs are, therefore, more likely due to genetic 
than environmental factors [1,3,4]. An understanding of 
the pharmacogenetics of FMOs would help predict 
interindividual variation in drug response and efficacy 
and, thus, contribute to drug development. This review 
considers the role of FMOs and their genetic variants in 
disease and drug response. 
Mechanism and structure  
For catalysis FMOs require flavin adenine dinucleotide 
(FAD) as a prosthetic group, NADPH as a cofactor and 
molecular oxygen as a cosubstrate [5,6]. In contrast to 
CYPs FMOs accept reducing equivalents directly from 
NADPH and, thus, do not require accessory proteins. 
Preferred substrates contain, as the site of oxygenation, a 
soft nucleophilic heteroatom such as nitrogen, sulfur, 
selenium or phosphorous. Products of FMO-catalyzed 
reactions are generally more polar and excretable and less 
toxic or pharmacologically active than the parent 
compound. FMOs have an unusual mechanism of action 
(Figure 1), which enables them to activate oxygen, in the 
form of stable hydroperoxyflavin, in the absence of bound 
substrate [5,6]. The enzyme, thus, is present in an 
activated form that can oxidize any soft nucleophile 
capable of gaining access to the active site. This unusual 
feature of FMOs accounts for their broad substrate range.  
The structure of a FMO of the yeast 
Schizosaccharomyces pombe recently has been determined 
[7] (Figure 2a). The protein is composed of two structural 
domains, a large domain and a small, or insertion, 
domain, with a channel between them. FAD only interacts 
with the large domain, the flavin being exposed to the 
channel. NADPH binds, via its adenine group, to the 
insertion domain, its nicotinamide group stacking, via 
hydrogen-bonding, to the exposed isoalloxazine ring of 
FAD. The crystal structure of the yeast enzyme–substrate 
complex indicates that the enzyme does not form the 
expected quaternary complex with FAD, NADPH and 
substrate. Instead, the substrate (methimazole) 
apparently competes with, and replaces, NADPH; it stacks 
with the isoalloxazine ring, making no direct contact with 
the polypeptide (Figure 2b). 
The structural evidence indicates striking differences in 
catalytic mechanism from that deduced from 
spectrophotometric and kinetic studies of mammalian 
FMOs [5,6,8]. The yeast enzyme is predicted to exist in the 
cell as an enzyme–FADH2–NADP+ complex, and there is 
no evidence for a stable hydroperoxyflavin form in the 
absence of substrate. Instead, the structure indicates 
simultaneous binding of substrate and molecular oxygen, 
with the latter being positioned near the isoalloxazine ring 
by H-bonding to Asn91, the only amino-acid residue for 
 
 which there is evidence of direct involvement in catalysis 
(Figure 2b). This suggests that in the yeast FMO, dioxygen 
acceptance occurs only in the presence of substrate and 
that 4a-hydroperoxyflavin represents a transient 
intermediate, rather than the stable intermediate, in 
mammalian FMOs (see Figure 1). 
It is not clear to what extent the mechanism deduced 
from the structure of the cytosolic yeast enzyme reflects 
that of mammalian FMOs, which are located in the 
membranes of the endoplasmic reticulum. The substrate 
range of the S. pombe FMO is not known. However, the 
substrate range of the FMO of another yeast, 
Saccharomyces cerevisiae, is more restricted than that of 
mammalian FMOs [9], reflecting its role in maintaining 
redox balance in the cell [10]. The ability of mammalian 
FMOs to metabolize a broad range of foreign chemicals 
might be a consequence of differences in catalytic 
mechanism that arose during evolution. 
The FMO family of humans 
Initial research on the FMOs of human was driven largely 
by the quest to identify the molecular basis of the 
inherited disorder trimethylaminuria (TMAuria) (see 
below). We now know that humans possess five functional 
FMO genes (FMO1 to FMO5) [11–13]. FMO1 to FMO4 are 
clustered on chromosome 1 at q24.3 [13], along with a 
pseudogene, FMO6P [13,14]. FMO5 is located ~26 Mbp 
closer to the centromere, at 1q21.1 [13]. A second FMO 
gene cluster, composed of five pseudogenes (FMO7P to 
FMO11P), is present at 1q24.2 [13]. The five functional 
FMO genes are thought to have arisen, via duplications of 
an ancestral gene, some 210–275 million years ago [13]. 
The proteins they encode have 51% to 57% amino acid 
sequence identity [12]. Of these, FMOs 1 and 3 have been 
implicated in disease and FMOs 1, 2 and 3 are the most 
important in the metabolism of foreign chemicals [1–3]. 
This review concentrates on the roles of FMOs 1, 2 and 3 
and their genetic variants in disease and drug metabolism. 
FMOs and disease 
FMO3 and TMAuria  
Loss-of-function mutations in FMO3 cause the disorder 
TMAuria [15,16], which is inherited in a recessive 
manner. Affected individuals are unable to metabolize the 
smelly free amine trimethylamine (TMA) to its non-
odorous N-oxide [17,18]. TMA is derived from dietary 
precursors, such as choline and lecithin, by the action of 
gut bacteria. The disorder is sometimes called fish-odor 
syndrome because sufferers secrete excessive amounts of 
TMA in their breath, sweat and urine, which imparts an 
odor resembling that of rotting fish. Although no physical 
symptoms are associated with TMAuria, the unpleasant 
odor characteristic of the disorder often results in 
psychological and social problems, in extreme cases 
leading to clinical depression and suicidal tendencies [17].  
The incidence of heterozygotes in British Caucasians is 
about 1%, but in other populations it might be 
considerably higher [19]. More than 30 distinct causative 
mutations have been identified (Figure 3) [3,18,20]. Some 
prevent binding of FAD and, thus, impair assembly of the 
holoenzyme, whereas others affect kinetic competency 
[21]. TMAuria sufferers lack functional FMO3. 
Consequently, their ability to metabolize FMO3 drug 
substrates, such as the nonsteroidal anti-inflammatory 
drug benzydamine, will be impaired [22]. 
Historical references to individuals who might have 
suffered from TMAuria include the description of 
Satyavati, a young woman who smelled of rotting fish, in 
the ‘Mahabharata’, an Indian epic compiled in about AD 
400, and Trinculo’s description of Caliban in 
Shakespeare’s ‘The Tempest’ [17]. Despite understanding 
its genetic basis, the disorder has no cure and causes 
much misery to those who are affected. Treatment 
strategies rely on dietary restriction of TMA precursors 
and suppression of intestinal production of TMA 
[17,18,23–25].  
Associations of FMO1 with disease 
Gene expression profiling indicates that the FMO1 gene is 
down-regulated in the spinal cord of patients with the 
neurodegenerative disease amyotrophic lateral sclerosis 
(ALS) [26]. A recent study [27] found that two single-
nucleotide polymorphisms (SNPs), located within the 3′ 
UTR of the mRNA, were overrepresented in female, but 
not male, sporadic ALS patients. In contrast FMO1 
expression is increased in the myocardial tissue of patients 
with atrial fibrillation (AF) [28]. Although these findings 
are intriguing, the potential role of FMO1 in the etiology 
of these diseases remains to be established. 
FMOs and drug metabolism 
Tissue distribution and regulation of expression 
Although FMO1 and FMO3 have some substrates in 
common, for example tamoxifen [29] and thiacetazone 
[30], their tissue distribution differs. Consequently, the 
relative contribution of a particular FMO to the 
metabolism of a drug will be tissue dependent. 
 In adult humans the main site of expression of FMO1 
is the kidney [12,31–33]. In this organ the amount of 
FMO1 [33] exceeds that of the total content of CYPs [34] 
and approaches that observed in the liver for the major 
hepatic CYP CYP3A4 [35]. FMO1 is, thus, likely to play an 
important role in the renal metabolism of drugs. The 
FMO1 gene is expressed in fetal human liver [12,31–
33,36], but its expression is extinguished just after birth 
[36]. Thus, in the adult human FMO1 makes no 
contribution to the hepatic metabolism of drugs. The lack 
of FMO1 expression in adult human liver [12,31–33,36] is 
in contrast to all other mammals investigated, in which 
FMO1 represents a major hepatic form of the enzyme. 
LINE-1 elements upstream of the core liver promoter of 
FMO1 act as powerful transcription repressors, which 
might account for the silencing of the gene in the adult 
human liver [37]. Expression of FMO1 in adult human 
extrahepatic tissues can be explained by the use of 
alternative, tissue-specific promoters [13,37].  
Of the FMOs involved in drug metabolism, FMO3 is the 
main form present in the adult human liver [12,13,32], 
which is not the case in other mammals investigated. The 
age at which the gene is switched on varies from birth to 
up to two years old, but by 10 months of age most 
individuals are expressing the enzyme [36]. FMO3 
 
 expression continues to increase until adulthood [36], by 
which stage the enzyme is present in amounts similar to 
those of CYP2C9, which represents about 20% of total 
hepatic CYPs [35].  
The delay between silencing of the FMO1 gene and the 
full activation of FMO3 means that during the first year of 
life many children have no, or very little, drug-
metabolizing FMOs in their liver.  
Genetic Polymorphisms and Drug Metabolism 
FMO3 
FMO3 metabolizes a number of drugs, including the 
antipsychotics amphetamine and clozapine, the 
monoamine oxidase B inhibitor deprenyl, the 
psychostimulant metamphetamine, the antiestrogen 
tamoxifen, the antituberculars ethionamide and 
thiacetazone and the activated form of the nonsteroidal 
anti-inflammatory agent  sulindac sulfide (reviewed in 
Refs [1,3]). 
 FMO3 is highly polymorphic, with as many as 15 
nonsynonymous SNPs identified, many of which are 
present at relatively high frequency (reviewed in Refs 
[3,4]). Individually, most of the SNPs have little or no 
effect on enzyme activity [1–4,38]. Three, however, do 
affect activity: g.11177C>A(N61K) causes a dramatic 
decrease in enzyme activity towards four different 
substrates [39], g.21599T>C(L360P) increases catalytic 
activity 2- to 5-fold [40] and is the only SNP known to 
increase FMO3 activity and g.15550C>T(R205C) has a 
moderate effect on enzyme activity but, interestingly, 
exhibits substrate inhibition of sulindac sulfide S-
oxygenation [41]. However, each of the three SNPs is 
present in low frequency and/or is restricted to single 
population groups [dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP)]. 
Consequently, they have limited significance for the 
general population.  
In Europeans and Asians the two most common SNPs, 
g.15167G>A(E158K) [15,42] and g.21443A>G(E308G) [16], 
are often linked, occurring on the same chromosome [43–
46]. The compound variant (E158K/E308G) can result in a 
reduction of enzyme activity, the extent of which depends 
on the substrate [2–4,38,40,41,46]. Homozygotes for 
158K/308G can exhibit symptoms of mild or transient 
TMAuria [47,48]. Many of the reported cases, however, are 
of young children, in whom low expression of FMO3 [36] 
(see above) might contribute to symptoms.   
A reduced FMO3 activity can be advantageous. For 
instance, the FMO3 genotype influenced the clinical 
outcomes of individuals treated with the nonsteroidal anti-
inflammatory drug sulindac and who had, or were 
predisposed to, familial adenomatous polyposis (FAP): 
those homozygous for 158K or 308G FMO3 variants did 
not develop polyps [49]. Individuals already suffering from 
FAP showed polyp regression associated with the FMO3 
genotype: only those homozygous or heterozygous for the 
158K allele or heterozygous for both 158K and 308G 
alleles showed a reduction in polyp number [50]. Sulindac 
is a prodrug converted by gut bacteria to its active 
metabolite, sulindac sulfide, which is then absorbed 
[51,52]. FMO3 then catalyzes the oxygenation of sulindac 
sulfide [53] to its inactive sulfoxide [54]. It is thought that 
enhanced sulindac efficacy in patients with E158K and 
E308G variants is the result of decreased oxidation of 
sulindac sulfide by FMO3, leading to an increase in the 
amount of active drug.  
Genetic variants that affect the amount of FMO3 
produced also have been identified [55]. Seven SNPs were 
identified in the 5′-flanking sequence of FMO3, from which 
15 haplotypes were inferred. In comparison with the 
reference sequence, one of the variant haplotypes 
increased transcription of a FMO3-reporter gene construct 
8-fold. If the increased activity observed in vitro is 
reflected in vivo, individuals with this haplotype, 
particularly homozygotes, would be expected to metabolize 
FMO3 substrates more rapidly, leading to a potential 
reduction in drug efficacy. Although this haplotype is 
present in relatively high frequency, it is often associated 
with the linked variant E158K/E308G [39]. In this case an 
increase in the amount of protein produced, via promoter 
SNPs, might compensate for an enzyme with lower 
activity due to coding SNPs. The presence of such linked 
SNPs might explain some of the discrepancies between 
results of analyses of mutant enzyme activity in vitro and 
drug metabolism in vivo. Two of the promoter-region 
haplotypes resulted in very low transcriptional activity in 
vitro [55]. However, each of these is present at low 
frequency in a single population group and, thus, would 
have little relevance for the general population. 
Analysis of genetic variation in FMO3 provides strong 
evidence that the gene has been the subject of balancing 
natural selection [56]. Balancing selection results in two or 
more haplotypes being maintained at higher frequencies 
than expected under a neutral model of evolution. In 
addition to the ancestral FMO3 haplotype, two variant 
haplotypes have been maintained. One contains both 
E158K and E308G SNPs and, thus, would encode an 
enzyme with a reduced activity. The other contains the 5′-
flanking SNPs that cause an 8-fold increase in promoter 
activity (see above). The natural selection of haplotypes 
that increase or decrease the amount or activity of FMO3 
suggests that the resulting metabolic versatility conferred 
an advantage during human evolution. 
FMO2 
FMO2 is an example of a gene that is en route to becoming 
a pseudogene in humans. Most individuals are 
homozygous for a C>T mutation that changes a glutamine 
codon at position 472 to a stop codon [57]. The resultant 
allele (FMO2*2A) encodes a truncated polypeptide that 
lacks 64 residues from its carboxy-terminus and is 
catalytically inactive [57]. The nonsense mutation 
g.23238C>T(Q472X) is not present in our closest relatives, 
chimpanzee (Pan troglodytes) and gorilla (Gorilla gorilla) 
[57], and, therefore, arose in the human lineage after the 
divergence of humans and chimps. The FMO2*2A allele 
subsequently spread to attain a frequency of essentially 
100% in all populations, with the exception of those of 
recent African descent in which the ancestral allele 
(FMO2*1), which encodes a full-length polypeptide, is 
present at appreciable frequencies [57,58]. The presence of 
 
 full-length active FMO2 in lung microsomes from an 
FMO2*1 individual has been confirmed [59]. The FMO2*1 
allele is present throughout sub-Saharan Africa, in some 
regions attaining frequencies as high as 26%, with almost 
50% of individuals having at least one FMO2*1 allele [60].  
Several other nonsynonomous SNPs have been 
identified [3,4,61], some of which abolish catalytic activity 
[62]. Haplotype analysis indicates that the loss-of-function 
SNPs occur on the FMO2*2A allele and, thus, are 
associated with a protein that is already inactive [62]. 
Individuals who possess a FMO2*1 allele, thus,  are likely 
to express a catalytically active protein. The distribution 
of FMO2*1 and FMO2*2A alleles among world 
populations has implications for interethnic and, in 
African populations, interindividual variation in response 
to drugs and in susceptibility to toxic chemicals that are 
substrates of FMO2, particularly those for which the lung 
is the target organ or route of entry.  
FMO2 catalyzes the oxygenation of a number of sulfur-
containing environmental chemicals. It detoxifies the 
thioether-containing organophosphate insecticides phorate 
and disulfoton [63] but converts thiourea and some of its 
derivatives to sulfenic or sulfinic acid metabolites, which 
are more toxic than the parent compound [64]. Thus, 
individuals who express functional FMO2 might have a 
reduced risk of toxicity if exposed to organophosphates but 
a greater risk from exposure to thioureas. Although little 
is known about drug substrates for human FMO2, it 
recently has been found to be capable of oxygenating the 
antitubercular drugs ethionamide and thiacetazone 
(A. Francois et al., unpublished), which has consequences 
for the efficacy and toxicity of these drugs in African 
populations.  
FMO1 
Of the three FMOs described in this review, FMO1 has the 
broadest substrate range, which includes the 
antidepressant imipramine, the antipsychotic 
chlorpromazine, the gastroprokinetic itopride and the 
antihistamine olopatadine (for a more complete list of 
FMO1 substrates, see Refs [1,3]).  
In contrast to FMO2 and FMO3, few nonsynonymous 
SNPs have been identified in FMO1 [3,4,61]  and each is 
confined to a single population group in which it is present 
at low frequency [3]. Three of the four SNPs tested had 
little or no effect on catalytic activity [65]. The other, 
g.27362C>T(R502X), which was identified in only 1 of 100 
chromosomes [61], completely abolished activity towards 
methimazole but had no effect on activity towards three 
other substrates [65].  
Interindividual variations in the amount of FMO1 
protein have been reported [4, 36]. A number of SNPs have 
been identified close to the fetal liver-specific FMO1 
promoter [66]. Only one, g.-9536C>A, was located in an 
element previously implicated in transcriptional 
regulation of the gene [67]. This SNP, located in a YY1 
element,  prevented binding of the transcription factor and 
decreased promoter activity in vitro [66]. However, the 
SNP (the FMO1*6 allele), which is present in relatively 
high frequency, was not correlated with lower FMO1 
expression in fetal liver in vivo [66]. No SNPs yet have 
been identified in the alternative FMO1 promoters active 
in extrahepatic tissues [37].  
An indication of the importance of FMO1 in drug 
detoxification is demonstrated by a recent study on Fmo1-
deficient mice (D. Hernandez et al., unpublished). When 
treated with the antidepressant imipramine, which is 
normally converted to its N-oxide by FMO1, the mice 
display an adverse reaction. This is accompanied by a 
marked increase in the amount of parent drug in the 
serum and kidneys and higher amounts of the metabolite 
desipramine in the brain, indicating that in the absence of 
FMO1 more of the drug is metabolized via CYP-mediated 
pathways.  
Concluding remarks 
The main features of the three FMOs involved in the 
metabolism of foreign chemicals are summarized in 
Table 1. FMOs catalyze the oxygenation of a wide variety 
of drugs and other foreign chemicals. The broad substrate 
range of the enzymes is a consequence of their unusual 
mechanism of action. Several genetic variants of FMOs of 
human have been identified. Loss-of-function mutations in 
FMO3 cause TMAuria, a disorder characterized by an 
unpleasant body odor that often results in psychological 
and social problems. More common polymorphic variants 
of FMO3, particularly when present in cis, can affect the 
amount or activity of the enzyme and, hence, alter drug 
efficacy. Some of these variants have been maintained 
during human evolution and, thus, might confer a 
selective advantage.  
Most people have a nonsense mutation that renders 
FMO2 inactive. However, a substantial minority of sub-
Saharan Africans express functional FMO2 and, thus, 
might be at greater risk of toxicity when exposed to 
chemicals, such as thioureas, that the enzyme converts 
into toxic products. Although FMO1 has the widest range 
of drug substrates, its expression in the human liver is 
silenced at birth and its contribution to drug metabolism 
in the adult is, therefore, restricted to extrahepatic 
tissues.  
Recent work on FMOs of humans, particularly the 
identification of genetic variants and the consequences of 
these for disease and drug response, has increased 
awareness of the pharmacological and toxicological 
significance of these enzymes. Future work should help 
define the contributions of FMOs to multipathway drug 
metabolism and enable us to predict how genetic variation 
in FMOs might lead to adverse drug reactions or enhanced 
drug efficacy. 
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Figure 1. The catalytic cycle of mammalian FMOs. Evidence for the cycle is based on spectrophotometric and kinetic studies (reviewed in Refs [5,6]). The cofactor NADPH binds 
and reduces the prosthetic group FAD to FADH2, via hydride ion transfer (step 1). Molecular oxygen then binds and is reduced, forming 4a-hydroperoxyflavin (4a-HPF or FADH-
 
 OOH) (step 2), which is stabilized by NADP+. Steps 1 and 2 are fast. The 4a-HPF, the structure of which is shown, is a stable intermediate and is considered to be the form in 
which FMO is present in the cell. Oxygenation of substrate S to SO occurs via nucleophilic attack on the distal O atom of 4a-HPF, leaving FAD as the 4a-hydroxyflavin (FADH-
OH) (step 3). The rate-limiting step is the release of water from the 4a-hydroxyflavin to reform FAD (step 4) and consequently the value of kcat should be independent of the 
structure of S. The final step is the release of NADP+ (step 5). 
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Figure 2. Structure of FMO of Schizosaccharomyces pombe. (a) Protein structure (taken from Protein Data Bank ID code 2GV8). The polypeptide is shown as a ribbon 
representation, and FAD and NADPH as stick models. NADPH is shown in red; for FAD carbon is depicted in green, oxygen in red and nitrogen in blue. (b) Active center 
depicted from above the isoalloxazine ring of FAD (taken from PDB ID code 2GVC). FAD, Asn at position 91 and the substrate methimazole are shown as stick models. Oxygen 
is depicted in red, nitrogen in blue and sulfur in yellow. 
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Figure 3. Mutations in FMO3 that cause TMAuria. The grey horizontal bar represents the FMO3 protein. The positions of the FAD- and NADPH-binding sites (white boxes) are 
indicated by arrows. Mutations in FMO3 are shown above and below the bar. Identification of the mutations was facilitated by determination of the intron–exon structure of the 
FMO3 gene [75]. P153L (shown in bold) was the first causative mutation identified [15]. This and E305X [16] are the most common. All of the mutations either abolish or severely 
impair catalytic activity. However, although N61S abolishes TMA N-oxygenation, it does not affect S-oxygenation of methimazole [76]. N61K, a polymorphic variant that severely 
impairs enzyme activity [39] and, thus, is predicted to cause TMAuria, has not been identified in affected individuals and, therefore, is not included in the figure. 
Table 1. Features of the FMOs involved in foreign chemical metabolism 
Gene 
Main site of 
expression Links to disease Examples of substrates1 
Some functionally 
significant SNPs SNP effect 
N61K Activity decreased or abolished [39]
R205C Activity moderately decreased [41] 
L360P Activity increased [40] 
E158K/E308G Activity moderately decreased [2–
4,38,40,41,46] 
Can cause transient TMAuria in 
children [47,48] 
Increased efficacy of sulindac 
[49,50] 
FMO3 Adult liver Loss-of-function mutations 
cause TMAuria2 
 
Adverse drug reactions or 
increased drug efficacy 
 
amphetamine [68,69] 
benzydamine [22] 
ethionamide [1] 
clozapine [70] 
deprenyl [69] 
metamphetamine [68,69] 
tamoxifen [71] 
thiacetazone [30] 
sulindac sulfide [53] 
Various promoter SNPs Either increase or decrease 
expression [55] 
FMO2 Lung Response to drugs and 
environmental chemicals 
disulfoton [63] 
phorate [63] 
thiourea-based drugs [64]  
Q472X3 
 
Activity abolished [57] 
R502X Substrate-dependent abolition of 
activity [65] 
FMO1 Fetal liver 
Fetal kidney 
Adult kidney 
Small intestine 
Decreased expression in 
spinal cord in ALS 
 
Increased expression in 
mycocardium in AF 
 
Response to drugs 
chlorpromazine [72] 
imipramine [72] 
itopride [73] 
olopatidine [74] 
tamoxifen [71] 
thiacetazone [30] 
Promoter SNPs Decrease expression [66] 
1In many cases FMO is not the only enzyme involved in the metabolism of  the chemical in vivo, 
2More than 30 causative mutations have been identified [3,18,20], 
3Other SNPs have been identified, but occur on a Q472X background [62]. 
 
 
